Built Here, Sold Abroad: Why Canada keeps losing the innovations it paid to create.

A Canadian diagnostic test can clear its trials, get published, prove it beats the current standard, and still never reach a Canadian patient. The science doesn't fail. The system around it does. Once the evidence is in, a Canadian health innovation still has to pass three gates: a payer willing to reimburse it, a first customer willing to buy it, and investors willing to fund the years in between. At every one of those gates, Canada built the front half of the system and left the back half voluntary. And at every one, someone outside Canada is waiting with a cheque. I keep running into this pattern on the Breaking Innovation Paralysis podcast. Follow one proven test through those three gates and you can watch it happen.

𝗚𝗮𝘁𝗲 𝟭: 𝗧𝗵𝗲 𝗽𝗮𝘆𝗲𝗿

Start with something mundane: a stool ova and parasite exam. For a standard stool ova and parasite exam, Ontario's lab schedule carries a lower baseline technical fee that aggregates to roughly $25 when combined with routine collection and handling footprints. British Columbia's lab medicine schedule lists up to $46.93 for the same examination. It's the same test, platform, reagents and staff, with almost twice the payout depending on which side of the Rockies you're on.

Dr. Anu Rebbapragada D(ABMM) FCCM CIC is a clinical microbiologist, a diagnostics leader for more than 20 years, and a member of Canada's first national AI-in-healthcare standards committee. She calls this the postal code lottery. Canada has thirteen jurisdictions and thirteen fee schedules, and no single body is accountable for making sure a proven Canadian test gets paid for in Canada. Each province can say yes. None is obligated to.

The result is what she calls pilot purgatory. Labs are so stretched keeping yesterday's fax-dependent workflows running that they have no bandwidth to adopt something better, even when everyone agrees it is better. She calls it institutional inertia, and she has watched it from the inside for two decades.

The frustrating part is that we know the system can move. During COVID, Canada stood up home collection, point-of-care testing and virtual results portals, quickly and safely. Then the pressure lifted and we went back to the old defaults. Capability was never the constraint. Obligation was.

Medicines face the same maze on a larger scale. Dr. Kostas Trakas, a former J&J executive and co-founder of Exsilios Pharma, points out that a new medicine has to clear three separate, closed-door processes (PMPRB, CDA-AMC and pCPA) before provinces will pay for it. His figure: Canadians can access 18% of globally available medicines, against an OECD average of 28%. His fix is to collapse the three into one agency.

𝗚𝗮𝘁𝗲 𝟮: 𝗧𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿

Suppose our test company tries a different route and sells to government directly. Canada has a program built for exactly that. Innovative Solutions Canada has been running since 2017 and is modelled on the US Small Business Innovation Research (SBIR) program. The difference is in the plumbing.

US law requires every federal agency with an extramural R&D budget over $100 million to set aside at least 3.2% of it for small businesses. That's more than $4 billion a year across 11 agencies. The part that matters most is Phase III. Once a company clears the R&D phases, the agency that funded it can buy the finished product directly, without a separate procurement competition. Government moves from funder to first customer.

Innovative Solutions Canada runs on roughly $100 million a year, funded by departments voluntarily setting aside about 1% of their procurement and R&D budgets. Budget 2025 added $79.9 million over five years and a new Small Business Procurement Program. Still, there's no legislated set-aside and no purchasing target. The program can fund a pilot, but it can't promise a company that a successful pilot becomes a contract. It's pilot purgatory again, this time with Ottawa as the landlord.

𝗚𝗮𝘁𝗲 𝟯: 𝗧𝗵𝗲 𝗰𝗮𝗽𝗶𝘁𝗮𝗹

All of this takes years, and years take money. The make-or-break stage for a life sciences company is the Series B and C round. That's where it either becomes a domestic anchor or gets acquired and moved abroad. It's also where Canadian capital is thinnest, which is strange for a country holding one of the largest pools of patient capital in the world.

From 1971 to 2005, a "foreign property rule" limited how much of a pension plan or RRSP could be held outside Canada. The limit started at 10% and rose to 30% by 2001. Budget 2005 eliminated it. The logic was sound: let pension managers chase the best risk-adjusted returns wherever they are.

Twenty years of compounding later, the Maple 8, Canada's largest public pension managers, collectively oversee well over a trillion dollars. They hold huge books of US and European private equity, infrastructure and buyouts. No rule stops them from backing a Canadian biotech, but no rule asks them to either. At their scale, a $20 million Series B can look like a rounding error that isn't worth the diligence. Kostas calls this the pension fund paradox.

There's one instructive exception. CDPQ, Quebec's pension manager, operates under a statutory dual mandate: generate returns and contribute to Quebec's economic development. That mandate keeps part of its capital looking for opportunities at home, including in Quebec's life sciences sector. A dual mandate isn't a departure from fiduciary duty. It's a governance choice, and every other province declined to make it.

𝗧𝗵𝗲 𝗲𝗻𝗱𝗶𝗻𝗴 𝘄𝗲 𝗸𝗲𝗲𝗽 𝘄𝗿𝗶𝘁𝗶𝗻𝗴

Now put the three gates together. Our company has a proven test. Provinces won't commit to paying for it, government won't commit to buying it, and domestic investors won't commit to funding the wait. Then a US or European strategic buyer calls with an offer.

Kostas calls what happens next the "second banana" mindset: founders take the first good offer instead of trying to build the next Shopify. It's easy to blame the founders. But when every door at home is a maybe, the offer from abroad is the only yes on the table. The company leaves, the IP leaves, and the jobs follow. A few years later, Canadian health systems buy the product back at full price. Canada paid for the research, then pays again for the result.

𝗧𝗵𝗲 𝗳𝗶𝘅 𝗶𝘀 𝗮 𝗴𝗼𝘃𝗲𝗿𝗻𝗮𝗻𝗰𝗲 𝗰𝗵𝗼𝗶𝗰𝗲

None of these gates needs a new program. Each needs the back half of an existing one made mandatory.

✅ Payers: one body accountable for moving a proven diagnostic or medicine to Canadian patients, instead of thirteen fee schedules and three sequential drug reviews that can each say maybe forever.

✅ First customer: a legislated set-aside within Innovative Solutions Canada, plus an SBIR Phase III-style route from a successful pilot to a production contract with the department that funded it.

✅ Capital: a CDPQ-style dual mandate for other public pension managers, requiring part of their capital to look seriously at Canadian scale-ups without dictating where it lands.

That's the thread connecting all three. Canada's innovations rarely die at the lab bench. They die in the gaps where everyone is allowed to say yes and no one is required to.

📰 LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter

🎧 Podcast: https://augmentios.com/podcast

#BreakingInnovationParalysis #LifeSciences #HealthPolicy #InnovationPolicy #CanadianInnovation